摘要来源： j transf med。 2016; 14（1）：237。 EPUB 2016 8月5日PMID： 27495782 27495782
Meng Li
Abstract:BACKGROUND: Hyperlipidemia is a major component of metabolic syndrome, and often predicts cardiovascular diseases.我们开发了一种新的治疗剂Berberine化合物（BC），该化合物由Berberine，Oryzanol和Vitamin B6组成，并确定了它们的抗Hyperlipidemia活性和潜在的机制。
方法： 雄性Wistar大鼠被喂食高脂饮食（HFD）诱导高脂血症，然后口服BC 4周。每周记录体重和食物摄入量，并在生物化学上确定血清中的脂质谱。 Metabolites in serum, urine, liver and feces were analyzed by GC-MS, and the structure of microbiota was determined by 16S rDNA sequencing.
RESULTS: Lipid lowering was observed in the hyperlipidemic rats upon BC treatment without apparent adverse side effects.代谢组学分析表明，BC治疗导致血清中的丙酮酸，血清素以及生酮和糖源性氨基酸水平增加，尿液中的吡啶多氧和4-吡啶氧酸含量增加，减少肝素和甲基氨基蛋白的肝素和甲基甲酸降低，并增加了甲基丙氨酸和减少脱氧和脱氧硅酸酯和lith的fecocochyChisty和lithEs lithecochtly和lith的fecocochy Conty Conty Conty conty conty conty conty Conty Conty inity inith in Conty inith inth inth inth inth s in consy conty inity inith inth conty。卑诗省的治疗也导致B富集eneficial bacteria (e.g. Bacteroides, Blautia) and a decrease in Escherichia.
CONCLUSIONS: The lipid lowering effect of BC treatment in hyperlipidemic rats is associated with a global change in the metabolism of lipids, carbohydrates and amino acids, as well作为微生物群的结构。